Literature DB >> 19001284

High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results.

Angelo Michele Carella, Monica Bellei, Pauline Brice, Christian Gisselbrecht, Giuseppe Visani, Philippe Colombat, Francesco Fabbiano, Amedea Donelli, Stefano Luminari, Pierre Feugier, Peter Browett, Hans Hagberg, Massimo Federico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19001284      PMCID： PMC2625418          DOI： 10.3324/haematol.13484

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease.

Authors:  M André; M Henry-Amar; D Blaise; P Colombat; J Fleury; N Milpied; J Y Cahn; J L Pico; Y Bastion; M Kuentz; G Nedellec; M Attal; C Fermé; C Gisselbrecht
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

3.  Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.

Authors:  D J Straus; J J Gaynor; J Myers; D P Merke; J Caravelli; D Chapman; J Yahalom; B D Clarkson
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.

Authors:  A M Carella; P Carlier; A Congiu; D Occhini; S Nati; G Santini; D Pierluigi; D Giordano; A Bacigalupo; E Damasio
Journal:  Bone Marrow Transplant       Date:  1991-08       Impact factor: 5.483

5.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

Authors:  Andrea Gallamini; Luigi Rigacci; Francesco Merli; Luca Nassi; Alberto Bosi; Isabella Capodanno; Stefano Luminari; Umberto Vitolo; Rosaria Sancetta; Emilio Iannitto; Livio Trentin; Caterina Stelitano; Silvia Tavera; Alberto Biggi; Antonio Castagnoli; Annibale Versari; Michele Gregianin; Ettore Pelosi; Pierfederico Torchio; Alessandro Levis
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

6.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

7.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Authors:  D Hasenclever; V Diehl
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

8.  High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.

Authors:  Massimo Federico; Monica Bellei; Pauline Brice; Maura Brugiatelli; Arnon Nagler; Christian Gisselbrecht; Luciano Moretti; Philippe Colombat; Stefano Luminari; Francesco Fabbiano; Nicola Di Renzo; Anthony Goldstone; Angelo Michele Carella
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544
  8 in total
  3 in total

Review 1.  A Review of Autologous Stem Cell Transplantation in Lymphoma.

Authors:  Umar Zahid; Faisal Akbar; Akshay Amaraneni; Muhammad Husnain; Onyee Chan; Irbaz Bin Riaz; Ali McBride; Ahmad Iftikhar; Faiz Anwer
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

2.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

3.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.